RT Journal Article SR Electronic T1 Early Spread of SARS-Cov-2 in the Icelandic Population JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.03.26.20044446 DO 10.1101/2020.03.26.20044446 A1 Daniel F Gudbjartsson A1 Agnar Helgason A1 Hakon Jonsson A1 Olafur T Magnusson A1 Pall Melsted A1 Gudmundur L Norddahl A1 Jona Saemundsdottir A1 Asgeir Sigurdsson A1 Patrick Sulem A1 Arna B Agustsdottir A1 Berglind Eiriksdottir A1 Run Fridriksdottir A1 Elisabet E Gardarsdottir A1 Gudmundur Georgsson A1 Olafia S Gretarsdottir A1 Kjartan R Gudmundsson A1 Thora R Gunnarsdottir A1 Arnaldur Gylfason A1 Hilma Holm A1 Brynjar O Jensson A1 Aslaug Jonasdottir A1 Frosti Jonsson A1 Kamilla S Josefsdottir A1 Thordur Kristjansson A1 Droplaug N Magnusdottir A1 Louise le Roux A1 Gudrun Sigmundsdottir A1 Gardar Sveinbjornsson A1 Kristin E Sveinsdottir A1 Maney Sveinsdottir A1 Emil A Thorarensen A1 Bjarni Thorbjornsson A1 Arthur Löve A1 Gisli Masson A1 Ingileif Jonsdottir A1 Alma Moller A1 Thorolfur Gudnason A1 Karl G Kristinsson A1 Unnur Thorsteinsdottir A1 Kari Stefansson YR 2020 UL http://medrxiv.org/content/early/2020/03/30/2020.03.26.20044446.abstract AB BACKGROUND Limited data exist on how SARS-CoV-2 enters and spreads in the general population.METHODS In Iceland we used two strategies for SARS-CoV-2 testing. Targeted testing was conducted in individuals at high risk of being infected (n=4,551) who were symptomatic, had traveled to high-risk areas, or been in contact with infected individuals, and a population screening was performed of those who accepted an offer of free testing (n=5,502). We sequenced the genomes of SARS-CoV-2 from 340 positive individuals to establish the origin of the virus, how it spreads and mutates in the population.RESULTS On March 22 2020, 528 had tested positive for SARS-CoV-2 in the targeted testing group (11.6%) and 50 in the population screening group (0.9%, 95% CI: 0.7%-1.2%). This represents approximately 0.2% of the Icelandic population. Large fractions of the individuals who tested positive in both testing groups had traveled outside Iceland (38.4% and 34.0%, respectively). A smaller fraction of those under 10 years of age is positive than among all tested: 2.8% vs 12.3% for targeted testing (P=1.6e-9) and 0.0% vs 1.0% for population screening (P=0.031). Relatively fewer females were positive in the targeted testing than males (9.5% vs 14.6%, P=6.8e-9). SARS-CoV-2 in Iceland came from eight diverse clades, seven A clades and one B clade. The composition of clades was different between the two testing groups and changed with time. In the early targeted testing the main clades or 65.0% were A2a1 and A2a2 derived from skiing areas in Italy and Austria, respectively, but those reduced in frequency to 30.6% in the later targeted testing group and were overtaken by the A1a and A2a clades, the two most common clades in the population screening group.CONCLUSION SARS-CoV-2 has spread widely in the Icelandic population outside of the high-risk groups targeted for testing by the healthcare system. Several different strains of the virus cause these infections and the composition of known infections in Iceland changed rapidly. Children and females are less vulnerable to SARS-CoV-2 than adults and males. Hence, to contain the pandemic we must increase the scope of the testing.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequenced virus genomes have been deposited into GISAID.